Melinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSI
02 mai 2017 09h38 HE
|
Melinta Therapeutics
New Haven, Conn, May 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced an upcoming...
Melinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug Design
21 avr. 2017 09h56 HE
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that...
Melinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient Types
21 avr. 2017 09h37 HE
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that the...
Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017
19 avr. 2017 14h42 HE
|
Melinta Therapeutics
New Haven, Conn, April 19, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that there will...